Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03324282
Title First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma (GCISAVE)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital, Bordeaux
Indications

bladder urothelial carcinoma

Therapies

Cisplatin + Gemcitabine

Avelumab + Cisplatin + Gemcitabine

Age Groups: senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
CHU de Besançon Besançon France Details
CHU de Bordeaux Bordeaux France Details
Institut Bergonié Bordeaux France Details
Centre François Baclesse Caen France Details
Centre Léon Bérard Lyon France Details
Institut Paoli Calmettes Marseille France Details
Institut de cancérologie de l'Ouest - René Gauducheau Nantes France Details
Hôpital Européen Georges-Pompidou, AP-HP Paris France Details
Hôpital Saint-Louis, AP-HP Paris France Details
CHU de Poitiers Poitiers France Details
CHU de Strasbourg Strasbourg France Details
Institut Universitaire du Cancer de Toulouse - Oncopole Toulouse France Details
Institut Gustave Roussy Villejuif France Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field